Advertisement
Screener

ORAMED PHARMACEUTICALS INC. (ORMP) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

2.8 / 5 stars · 68/120 Roast Me

ORAMED PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

ORAMED PHARMACEUTICALS INC. (ORMP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 48.33 thousand shares for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-06.

Discontinued › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2023-03-06

  • ORAMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 48.33K shares.
  • ORAMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2021 was 52.58K shares, a 86.61% decline from fiscal 2020.
  • ORAMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2020 was 392.65K shares, a 188.53% increase from fiscal 2019.
  • ORAMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2019 was 136.08K shares.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month
2022-12-3148.33K shares
10-K · filed 2023-03-06
2021-08-3152.58K shares
10-K · filed 2023-03-06
2020-08-31392.65K shares
10-K · filed 2021-11-24
2019-08-31136.08K shares
10-K · filed 2020-11-24

Similar stocks

Stock NameCountryMarket CapPE Ratio
Zentalis Pharmaceuticals, Inc. (ZNTL)United States$0.196B-2.48
Nkarta, Inc. (NKTX)United States$0.205B-1.73
Fortress Biotech, Inc. (FBIO)United States$0.188B0.91
ALX ONCOLOGY HOLDINGS INC (ALXO)United States$0.187B-3.52
PepGen Inc. (PEPG)United States$0.186B-1.73
AN2 Therapeutics, Inc. (ANTX)United States$0.185B-4.84
Foghorn Therapeutics Inc. (FHTX)United States$0.213B-4.43
Organogenesis Holdings Inc. (ORGO)United States$0.182B-3.70
Eledon Pharmaceuticals, Inc. (ELDN)United States$0.219B-3.23
Whitehawk Therapeutics, Inc. (WHWK)United States$0.221B